 |
Tekmira Announces Election of Directors
May 17, 2013
|
7.7 KB |
|
| |
VANCOUVER, British Columbia, May 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that the nominees listed in the management proxy circular for the 2013 Annual and Special Meeting of Shareholders were elected as directors of Tekmira at th...
|
|
Tekmira Presents LNP Technology Innovations at Scientific Symposium
May 15, 2013
|
16.5 KB |
|
| |
VANCOUVER, British Columbia, May 15, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that data demonstrating its ongoing lipid nanoparticle (LNP) technology innovations and manufacturing related advancements were presented at the 15th Annual...
|
|
Tekmira Provides Corporate Update and Announces First Quarter 2013 Results
May 14, 2013
|
25.8 KB |
|
| |
VANCOUVER, British Columbia, May 14, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced its financial and operating results for the first quarter ended March 31, 2013 and provided a corporate update.
"Last month, we were pleased to pr...
|
|
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results
May 9, 2013
|
7.5 KB |
|
| |
VANCOUVER, British Columbia, May 9, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Tuesday, May 14, 2013 at 1:00 pm Pacific Time (4:00 pm Eastern Time) to provide a corporate update and rep...
|
|
Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola Program
May 8, 2013
|
15.2 KB |
|
| |
VANCOUVER, British Columbia, May 8, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that its contract with the U.S. Department of Defense (DoD) has been modified to support development plans that integrate advancements in Tekmira's lip...
|
|
Tekmira's Collaborators at the National Cancer Institute Present Preclinical Data at the Annual Meeting of the American Association for Cancer Research (AACR)
Apr 10, 2013
|
12.3 KB |
|
| |
VANCOUVER, British Columbia, April 10, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that its collaboration partner, the National Cancer Institute (NCI), will present preclinical data at the annual meeting of the American Association for C...
|
|
Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting
Apr 9, 2013
|
17.7 KB |
|
| |
TKM-PLK1 Resulted in Clinical Benefit in 44% of Evaluable Patients Receiving Doses in Effective RangeTekmira to Initiate a Phase II Clinical Trial in Gastrointestinal Carcinoid (Neuroendocrine) CancerConference Call at 4:30 pm ET Today
VANCOUVER, B.C., April 9, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM)...
|
|
Tekmira Provides Corporate Update and Announces Year-End Audited 2012 Results
Mar 27, 2013
|
26.5 KB |
|
| |
VANCOUVER, British Columbia, March 27, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced its 2012 audited financial results and provided a corporate update.
"Over the last year, Tekmira has contributed to significant advancements in ...
|
|
Tekmira Conference Call and Webcast Advisory: Corporate Update and Year-End 2012 Financial Results
Mar 20, 2013
|
7.5 KB |
|
| |
VANCOUVER, B.C., March 20, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Wednesday, March 27, 2013 at 1:30 pm Pacific Time (4:30 pm Eastern Time) to provide a corporate update and report y...
|
|
Tekmira Outlines Key 2013 Product Development and Corporate Milestones
Feb 12, 2013
|
19.6 KB |
|
| |
VANCOUVER, British Columbia, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today its key product development, corporate, and partner milestones for 2013.
"Tekmira has been at the forefront of the RNAi technology revolution ove...
|
|
Tekmira to Webcast Presentation at 15th Annual BIO CEO & Investor Conference
Feb 6, 2013
|
7.5 KB |
|
| |
VANCOUVER, British Columbia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that management will present a company overview at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 10:30 am ET (7:30 am...
|
|
Tekmira to Present TKM-PLK1 Phase 1 Clinical Trial Results at AACR
Feb 4, 2013
|
12.5 KB |
|
| |
VANCOUVER, British Columbia, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has been selected as an oral presenter at the annual meeting of the American Association for Cancer Research (AACR) taking place in Washington...
|
|
Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery
Jan 31, 2013
|
16.0 KB |
|
| |
VANCOUVER, British Columbia, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that complete study results have been published from a Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of adv...
|
|
Tekmira Acquires Worldwide License to Novel RNAi Technology
Nov 29, 2012
|
12.7 KB |
|
| |
VANCOUVER, British Columbia, Nov. 29, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (UNA) from Marina Biotec...
|
|
Tekmira Provides Corporate Update and Announces Third Quarter 2012 Results
Nov 13, 2012
|
25.0 KB |
|
| |
VANCOUVER, British Columbia, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today its financial and operating results for the third quarter ended September 30, 2012 and provided a corporate update.
On November 12, 2012, Tekmira...
|
|
Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter 2012 Results
Nov 12, 2012
|
8.0 KB |
|
| |
VANCOUVER, British Columbia, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Tuesday, November 13, 2012 at 4:30 am Pacific Time (7:30 am Eastern Time) to provide a corporate update ...
|
|
Tekmira and Alnylam Restructure Relationship and Settle All Litigation
Nov 12, 2012
|
16.6 KB |
|
| |
VANCOUVER, British Columbia, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) today announced that it has entered into a settlement agreement with Alnylam Pharmaceuticals, Inc. that resolves all litigation between the companies, and has signed a new licensing agreement that restructures the relationship ...
|
|
Tekmira Provides Update on Collaboration With U.S. Government's TMT Program
Oct 2, 2012
|
11.5 KB |
|
| |
VANCOUVER, British Columbia, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today disclosed that the temporary stop-work order announced on August 6, 2012 with respect to Tekmira's TKM-Ebola program has now been lifted by the U.S. Department ...
|
|
Tekmira Provides Update on Collaboration With U.S. Government's TMT Program
Sep 27, 2012
|
11.5 KB |
|
| |
VANCOUVER, British Columbia, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Department of Defense (DoD) has extended the period of a temporary stop-work order with respect to Tekmira's TKM-Ebola program.
It...
|
|
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
Sep 26, 2012
|
12.5 KB |
|
| |
VANCOUVER, British Columbia, Sept. 26, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that its motions to dismiss for lack of standing and to disqualify Alnylam's counsel have been denied in the patent infringement lawsuit filed on January ...
|
|
|
